Commercial landscape of noninvasive prenatal testing in the United States

Ashwin Agarwal, Lauren C. Sayres, Mildred K. Cho, Robert Cook-Deegan, Subhashini Chandrasekharan

Research output: Contribution to journalReview article

84 Citations (Scopus)

Abstract

Cell-free fetal DNA-based noninvasive prenatal testing (NIPT) could significantly change the paradigm of prenatal testing and screening. Intellectual property (IP) and commercialization promise to be important components of the emerging debate about clinical implementation of these technologies. We have assembled information about types of testing, prices, turnaround times, and reimbursement of recently launched commercial tests in the United States from the trade press, news articles, and scientific, legal, and business publications. We also describe the patenting and licensing landscape of technologies underlying these tests and ongoing patent litigation in the United States. Finally, we discuss how IP issues may affect clinical translation of NIPT and their potential implications for stakeholders. Fetal medicine professionals (clinicians and researchers), genetic counselors, insurers, regulators, test developers, and patients may be able to use this information to make informed decisions about clinical implementation of current and emerging noninvasive prenatal tests.

Original languageEnglish (US)
Pages (from-to)521-531
Number of pages11
JournalPrenatal Diagnosis
Volume33
Issue number6
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Intellectual Property
Technology Transfer
Insurance Carriers
Jurisprudence
Prenatal Diagnosis
Publications
Research Personnel
Medicine
Technology
DNA
Counselors

ASJC Scopus subject areas

  • Genetics(clinical)
  • Obstetrics and Gynecology

Cite this

Commercial landscape of noninvasive prenatal testing in the United States. / Agarwal, Ashwin; Sayres, Lauren C.; Cho, Mildred K.; Cook-Deegan, Robert; Chandrasekharan, Subhashini.

In: Prenatal Diagnosis, Vol. 33, No. 6, 06.2013, p. 521-531.

Research output: Contribution to journalReview article

Agarwal, A, Sayres, LC, Cho, MK, Cook-Deegan, R & Chandrasekharan, S 2013, 'Commercial landscape of noninvasive prenatal testing in the United States', Prenatal Diagnosis, vol. 33, no. 6, pp. 521-531. https://doi.org/10.1002/pd.4101
Agarwal, Ashwin ; Sayres, Lauren C. ; Cho, Mildred K. ; Cook-Deegan, Robert ; Chandrasekharan, Subhashini. / Commercial landscape of noninvasive prenatal testing in the United States. In: Prenatal Diagnosis. 2013 ; Vol. 33, No. 6. pp. 521-531.
@article{f591608d1e59483ba9e7c82a20153272,
title = "Commercial landscape of noninvasive prenatal testing in the United States",
abstract = "Cell-free fetal DNA-based noninvasive prenatal testing (NIPT) could significantly change the paradigm of prenatal testing and screening. Intellectual property (IP) and commercialization promise to be important components of the emerging debate about clinical implementation of these technologies. We have assembled information about types of testing, prices, turnaround times, and reimbursement of recently launched commercial tests in the United States from the trade press, news articles, and scientific, legal, and business publications. We also describe the patenting and licensing landscape of technologies underlying these tests and ongoing patent litigation in the United States. Finally, we discuss how IP issues may affect clinical translation of NIPT and their potential implications for stakeholders. Fetal medicine professionals (clinicians and researchers), genetic counselors, insurers, regulators, test developers, and patients may be able to use this information to make informed decisions about clinical implementation of current and emerging noninvasive prenatal tests.",
author = "Ashwin Agarwal and Sayres, {Lauren C.} and Cho, {Mildred K.} and Robert Cook-Deegan and Subhashini Chandrasekharan",
year = "2013",
month = "6",
doi = "10.1002/pd.4101",
language = "English (US)",
volume = "33",
pages = "521--531",
journal = "Prenatal Diagnosis",
issn = "0197-3851",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Commercial landscape of noninvasive prenatal testing in the United States

AU - Agarwal, Ashwin

AU - Sayres, Lauren C.

AU - Cho, Mildred K.

AU - Cook-Deegan, Robert

AU - Chandrasekharan, Subhashini

PY - 2013/6

Y1 - 2013/6

N2 - Cell-free fetal DNA-based noninvasive prenatal testing (NIPT) could significantly change the paradigm of prenatal testing and screening. Intellectual property (IP) and commercialization promise to be important components of the emerging debate about clinical implementation of these technologies. We have assembled information about types of testing, prices, turnaround times, and reimbursement of recently launched commercial tests in the United States from the trade press, news articles, and scientific, legal, and business publications. We also describe the patenting and licensing landscape of technologies underlying these tests and ongoing patent litigation in the United States. Finally, we discuss how IP issues may affect clinical translation of NIPT and their potential implications for stakeholders. Fetal medicine professionals (clinicians and researchers), genetic counselors, insurers, regulators, test developers, and patients may be able to use this information to make informed decisions about clinical implementation of current and emerging noninvasive prenatal tests.

AB - Cell-free fetal DNA-based noninvasive prenatal testing (NIPT) could significantly change the paradigm of prenatal testing and screening. Intellectual property (IP) and commercialization promise to be important components of the emerging debate about clinical implementation of these technologies. We have assembled information about types of testing, prices, turnaround times, and reimbursement of recently launched commercial tests in the United States from the trade press, news articles, and scientific, legal, and business publications. We also describe the patenting and licensing landscape of technologies underlying these tests and ongoing patent litigation in the United States. Finally, we discuss how IP issues may affect clinical translation of NIPT and their potential implications for stakeholders. Fetal medicine professionals (clinicians and researchers), genetic counselors, insurers, regulators, test developers, and patients may be able to use this information to make informed decisions about clinical implementation of current and emerging noninvasive prenatal tests.

UR - http://www.scopus.com/inward/record.url?scp=84878130004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878130004&partnerID=8YFLogxK

U2 - 10.1002/pd.4101

DO - 10.1002/pd.4101

M3 - Review article

C2 - 23686656

AN - SCOPUS:84878130004

VL - 33

SP - 521

EP - 531

JO - Prenatal Diagnosis

JF - Prenatal Diagnosis

SN - 0197-3851

IS - 6

ER -